PBAC's latest decision on Palonosetron hydrochloride: Recommended with restriction (2010). Considered for Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2010
Submissions
1
2010 → 2010
Eligible population
patients receiving moderately or highly emetogenic chemotherapy
Therapy area
Oncology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
OS | PFS | DFS | ORR | QoL | Surrogate | Cost-minimisation | Other | null
Key trials
Aapro et al. (2006), Gralla et al. (2003), Eisenberg et al. (2003), Saito et al. (2009), Yu et al. (2009)
Comparator
ondansetron
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis conducted; no ICER calculated as submission assumed therapeutic equivalence